Faraday Pharma to Host Webinar on Preventing Ischemia-Reperfusion Injury in Acute STEMI

SEATTLE, July 16, 2024 — Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has announced it will host a virtual KOL (Key Opinion Leader) webinar on Tuesday, July 30, 2024, at 11:00 AM ET. The event will feature presentations from Dr. Cheerag Shirodaria of Oxford University Hospitals, Dr. Marc Bonaca from the University of Colorado Anschutz, and Dr. Antonio Gutierrez of Duke University Hospital and Durham VA Medical Center. These experts will discuss the current treatment landscape and unmet needs in preventing ischemia-reperfusion injury, which is critical in managing heart failure following acute ST-elevation myocardial infarction (STEMI).

The webinar aims to highlight the impact of STEMI on heart failure and other patient outcomes. Additionally, it will review data from the development of FDY-5301, an investigational product by Faraday Pharmaceuticals designed to minimize cardiac damage post-STEMI. The company's Phase 3 Iocyte AMI-3 trial of FDY-5301 in anterior STEMI patients undergoing primary percutaneous intervention is fully enrolled, with topline data expected in the second half of 2025. After the formal presentations, there will be a live question and answer session.

Dr. Cheerag Shirodaria, with extensive expertise in cardiac imaging and interventional cardiology, will be one of the key speakers. He has played a significant role in the design and execution of the Phase 2 STEMI trial involving FDY-5301 and is part of the Executive Steering Committee of the IOCYTE-AMI trial. Dr. Shirodaria’s background includes a medical degree from St Bartholomew's Hospital Medical College, a medical doctorate from the University of Oxford, and an MBA from the London Business School. He has also been instrumental in developing AI imaging tools for predicting cardiometabolic risks.

Dr. Marc Bonaca, another presenter, is a cardiologist and vascular medicine specialist known for his work in ischemic risk related to atherosclerotic vascular disease. He serves as the executive director of CPC and Director of Vascular Research & Professor of Medicine at the University of Colorado Anschutz. Dr. Bonaca has a medical degree from the University of Connecticut and an MPH from Harvard. His research has focused on designing and conducting large, multicenter randomized clinical trials, with notable involvement in several significant outcomes trials. His interests include peripheral artery disease (PAD), peripheral vascular disease (PVD), and diabetes, particularly concerning ischemic limb and microvascular complications.

Dr. Antonio Gutierrez, whose clinical interests are in diagnostic and interventional coronary angiography and vascular medicine, will also be speaking at the webinar. He has been involved in numerous clinical trials on atherosclerotic disease and holds a Doctorate of Medicine from Case Western Reserve University and a Masters of Health Science in Clinical Research from Duke University. Dr. Gutierrez is currently an Assistant Professor of Medicine at Duke University Hospital and a Staff Physician at the Durham VA Medical Center.

Acute STEMI remains one of the leading causes of cardiovascular death and heart failure. Standard treatment involves percutaneous coronary intervention (PCI) to restore blood flow. Reperfusion injury, which occurs when blood supply returns to the ischemic heart muscle, is a significant factor in patient outcomes.

FDY-5301, an elemental reducing agent containing sodium iodide, is being investigated by Faraday Pharmaceuticals for its potential to reduce ischemia-reperfusion injury (IRI). Preclinical models have shown that FDY-5301 reduces tissue damage, infarct size, and inflammation. It acts by neutralizing hydrogen peroxide, a reactive oxygen species involved in the IRI cascade, and functions as an immunomodulating agent. A Phase 2 trial of FDY-5301 in STEMI patients indicated that the drug was well-tolerated and showed promising signals of efficacy in reducing cardiac damage.

Faraday Pharmaceuticals is dedicated to preventing heart failure by minimizing myocardial damage in acute STEMI. Founded by Dr. Mark Roth and supported by ARCH Venture Partners and Polaris Partners, the company is headquartered in Seattle. The lead program, FDY-5301, is currently in a pivotal Phase 3 trial aimed at reducing IRI in acute STEMI.